Diagnostic Direct-To-Consumer Ads Will Increase With Rx Therapies – Root
This article was originally published in The Gray Sheet
Executive Summary
Diagnostic manufacturers increasingly will rely on patient-driven reimbursement strategies as diagnostic tests are used more frequently to determine appropriate drug therapy, according to consultant Charles Root, MCF Compliance president